BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau (Reuters) - U.S. generics drugmaker Mylan said on ...

(RTTNews) - Healthcare company Viatris Inc. (VTRS) said Wednesday that it won court decisions on Sanofi appeals of lantus patent invalidations. The court decisions affirmed the U.S. Patent and ...

BRIDGEWATER, N.J. A disposable insulin pen for patients ages 4 and older with Type 1 diabetes and adults with Type 2 diabetes has become available in the United States. Sanofi-Aventis U.S. announced ...

The US Court of Appeals for the First Circuit held that pharmaceutical companies that wrongly list patents in FDA’s Orange Book must prove they acted in good faith to avoid antitrust liability. In re ...

Co confirms (see 6:22 comment) that the FDA approved Lantus SoloStar, a new prefilled disposable insulin pen for once-daily 24- hour insulin LANTUS for the treatment of hyperglycemia in people with ...

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition. Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...